Cost of Revenue Comparison: Zoetis Inc. vs Amneal Pharmaceuticals, Inc.

Cost of Revenue: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, understanding cost structures is crucial. Zoetis Inc. and Amneal Pharmaceuticals, Inc. offer a fascinating comparison. Over the past decade, Zoetis has consistently maintained a higher cost of revenue, peaking at $2.71 billion in 2023, a 63% increase from 2014. This reflects its expansive operations and market reach. In contrast, Amneal Pharmaceuticals, Inc. has seen a more dramatic rise, with costs surging by 368% from 2014 to 2023, reaching $1.57 billion. This rapid growth underscores Amneal's aggressive expansion strategy. The data highlights the differing scales and strategies of these two industry players, offering insights into their operational efficiencies and market positioning. As the pharmaceutical sector continues to evolve, monitoring these trends will be key for investors and analysts alike.